|
KMID : 1202020100030020116
|
|
Journal of Korean Thyroid Association
2010 Volume.3 No. 2 p.116 ~ p.122
|
|
|
Development of New Therapeutics Based on Pathogenesis of Papillary Thyroid Cancer
|
|
Lee Min-Hee
Jo Young-Suk
Shong Min-Ho
|
|
|
Abstract
|
|
|
|
Papillary thyroid cancer (PTC) is the most common endocrine malignancy. The prognosis of PTC is defined primarily by the principal clinical features such as patient’s age, tumor size, histological subtypes, regional nodal metastasis, extra-thyroidal invasion and distant metastasis. Although PTC prognosis is excellent, adverse clinical features increase the probability of recurrence and progression. To improve patients’ survival and reduce recurrence and progression, advances in molecular biological insights for principal clinical features will beneeded. It has been recognized for years that aberrant kinase activation can induce cellular transformation, carcinogenesis and disease progression. Based on this concept, many investigators have been focusing on the development of new small molecules to inhibit the aberrant kinase activation and conducted clinical trials. In this review article, we describe the background for development of new targeted therapy and define molecular biological insights into the carcinogenesis of PTC.
|
|
|
KEYWORD
|
|
|
Papillary thyroid cancer, BRAFV600E, Sorafenib, PLX4720
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|